• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Protein Kinase Therapeutics in Oncology - Where to Commercialize? Product Image

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

  • Published: October 2009
  • Region: Global
  • 1442 Pages
  • Bioseeker

FEATURED COMPANIES

  • AB Science
  • BioAxone
  • Dyax
  • KAI Pharmaceuticals
  • OncoTherapy Science
  • Scancell
  • MORE

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic READ MORE >

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents
4.1 List of Figures
4.2 List of Tables

5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment
6.1 Drug Repositioning in Oncology
6.2 Introduction to Protein Kinase Therapeutic Targets in Oncology
6.2.1 Carboxy-lyase Activity Targets
6.2.2 Catalytic Activity Targets
6.2.3 Cell Adhesion Molecule Activity Targets
6.2.4 Chaperone Activity Targets
6.2.5 Cysteine-Type Peptidase Activity Targets
6.2.6 DNA Topoisomerase Activity Targets
6.2.7 G-Protein Coupled Receptor Activity Targets
6.2.8 Growth Factor Activity Targets
6.2.9 Hydrolase Activity Targets
6.2.10 Kinase Activity Targets
6.2.11 Kinase Regulator Activity Targets
6.2.12 Lipid Kinase Activity Targets
6.2.13 Lipid Phosphatase Activity Targets
6.2.14 Oxidoreductase Activity Targets
6.2.15 Peroxidase Activity Targets
6.2.16 Protein Binding Targets
6.2.17 Protein Serine/Threonine Kinase Activity Targets
6.2.18 Protein Threonine/Tyrosine Kinase Activity Targets
6.2.19 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets
6.2.20 Protein-Tyrosine Kinase Activity Targets
6.2.21 Protein-Tyrosine Kinase Activity Targets
6.2.22 Receptor Activity Targets
6.2.23 Receptor Binding Targets
6.2.24 Receptor Signaling Complex Scaffold Activity Targets
6.2.25 Structural Constituent of Cytoskeleton Targets
6.2.26 Transcription Factor Activity Targets
6.2.27 Transcription Regulator Activity Targets
6.2.28 Translation Regulator Activity Targets
6.2.29 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.30 Transporter Activity Targets
6.3 The Cancer Genome Project and Protein Kinase Therapeutic Targets in Oncology
6.3.1 Protein Kinase Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.4 Structure-based Drug Design in Protein Kinase Therapeutics is Stimulated by Available Structure Data on Biological Targets
6.5 Target-Target Interactions among Identified Protein Kinase Therapeutics Targets in Oncology
6.6 The Drug-Target Interactome
6.7 Protein Expression Levels of Identified Protein Kinase Therapeutic Targets in Oncology
6.8 Pathway Analysis of Cancer Protein Kinase Therapeutic Targets

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline?
7.1 Terminated Drug Target Profiles of Cancer Protein Kinase Drugs
7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Protein
Kinase Therapeutics in Oncology
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Protein Kinase
Therapeutics in Oncology
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Protein Kinase
Therapeutics in Oncology
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Protein Kinase
Therapeutics in Oncology
7.6 Preclinical Development: New and Unique Drug Target Profiles of Protein Kinase
Therapeutics in Oncology
7.7 Development Profiles of All Protein Kinase Drugs in Oncology

8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type
8.1 Small Molecules
8.1.1 Background
8.1.2 Target Profiles of Small Molecular Drugs
8.2 Peptide/Protein Drugs
8.2.1 Background
8.2.2 Target Profiles of Peptide and Protein Drugs
8.3 Antibodies and Antibody-like Structures
8.3.1 Background
8.3.2 Target Profiles of Antibody Drugs
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Target Profiles of Nucleic Acid Drugs
8.5 Cell and Gene Therapy
8.5.1 Background
8.5.2 Target Profiles of Cell- and Gene Therapy Drugs
8.6 The Competition Through Close Mechanistic Approximation of Cancer Protein Kinase Therapeutics
8.7 Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology

9 Selecting Cancer Indications for Protein Kinase Therapeutics
9.1 Acute Lymphocytic Leukemia
9.2 Acute Myelogenous Leukemia
9.3 Adrenal Cancer
9.4 B-cell Lymphoma
9.5 Basal Cell Cancer
9.6 Benign prostatic hyperplasia
9.7 Biliary Cancer
9.8 Bladder Cancer
9.9 Bone Cancer
9.10 Brain Cancer
9.11 Breast Cancer
9.12 Carcinoid
9.13 Cervical Cancer
9.14 Chronic Lymphocytic Leukemia
9.15 Chronic Myelogenous Leukemia
9.16 Colorectal Cancer
9.17 Endometrial Cancer
9.18 Fallopian Tube Cancer
9.19 Gastrointestinal Cancer (general)
9.20 Gastrointestinal Stomach Cancer
9.21 Gastrointestinal Stromal Cancer
9.22 Head and Neck Cancer
9.23 Hodgkin's Lymphoma
9.24 Leiomyo Sarcoma
9.25 Leukemia (general)
9.26 Lipo Sarcoma
9.27 Liver Cancer
9.28 Lung Cancer (general)
9.29 Lymphoma (general)
9.30 Mast Cell Leukemia
9.31 Melanoma
9.32 Mesothelioma
9.33 Myelodysplastic Syndrome
9.34 Myeloma
9.35 Nasopharyngeal Cancer
9.36 Neuroblastoma Cancer
9.37 non-Hodgkin's Lymphoma
9.38 Non-Small Cell Lung Cancer
9.39 Oesophageal Cancer
9.40 Oral Cancer
9.41 Osteo Sarcoma
9.42 Ovarian Cancer
9.43 Pancreatic Cancer
9.44 Peritoneal Cancer
9.45 Prostate Cancer
9.46 Renal Cancer
9.47 Rhabdomyo Sarcoma
9.48 Sarcoma (general)
9.49 Small Cell Lung Cancer
9.50 Soft Tissue Sarcoma
9.51 Squamous Cell Cancer
9.52 Synovial Sarcoma
9.53 T-cell Lymphoma
9.54 Testicular Cancer
9.55 Thymoma Cancer
9.56 Thyroid Cancer
9.57 Unspecified Cancer Indication

10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator
10.1 4SC
10.2 AB Science
10.3 Abbott
10.4 Abiogen
10.5 Abraxis BioScience
10.6 Advenchen
10.7 AEgera
10.8 Aeterna Zentaris
10.9 Aida Pharmaceuticals
10.10 Alethia Biotherapeutics
10.11 Alfacell
10.12 AlphaVax
10.13 Ambit Biosciences
10.14 Amgen
10.15 Amphora
10.16 Apthera
10.17 Ariad
10.18 Arno Therapeutics
10.19 ArQule
10.20 Array BioPharma
10.21 Astellas
10.22 Astex Therapeutics
10.23 AstraZeneca
10.24 Avalon
10.25 Bayer
10.26 Benitec
10.27 Berkeley Lab
10.28 BioAxone
10.29 Biotecnol
10.30 Biotica Technology
10.31 Boehringer Ingelheim
10.32 Bristol-Myers Squibb
10.33 BTG
10.34 Calistoga Pharmaceuticals
10.35 Callisto Pharmaceuticals
10.36 Cambrex
10.37 CanBas
10.38 Cancer Research Technology
10.39 Catalyst Biosciences
10.40 Celgene
10.41 Cell Therapeutics
10.42 Cephalon
10.43 Chroma Therapeutics
10.44 CompleGen
10.45 Compugen
10.46 CoNCERT Pharmaceuticals
10.47 Curis
10.48 Cyclacel
10.49 Cylene Pharmaceuticals
10.50 Cytokine PharmaSciences
10.51 Cytopia
10.52 Dainippon Sumitomo Pharma
10.53 Deciphera Pharmaceuticals
10.54 DeveloGen
10.55 Dyax
10.56 Eisai
10.57 Elara Pharmaceuticals
10.58 Eli Lilly
10.59 Enkam Pharmaceuticals
10.60 EntreMed
10.61 Exelixis
10.62 Galapagos
10.63 Genentech
10.64 Generex
10.65 GlaxoSmithKline
10.66 GlycoGenesys
10.67 GPC Biotech
10.68 Hanmi
10.69 Hoffmann-La Roche
10.70 Hutchison China MediTech
10.71 Idera Pharmaceuticals
10.72 ImClone Systems
10.73 ImmunoFrontier
10.74 Incyte Corporation
10.75 Inhibiton Therapeutics
10.76 Inovio
10.77 Insmed
10.78 InterMune
10.79 ISU ABXIS
10.80 Johnson & Johnson
10.81 KAI Pharmaceuticals
10.82 Kalypsys
10.83 Keryx Biopharmaceuticals
10.84 Kiadis
10.85 Kirin Pharma
10.86 KuDOS
10.87 Kyowa Hakko Kirin
10.88 Lexicon Pharmaceuticals
10.89 Locus Pharmaceuticals
10.90 Lorus Therapeutics
10.91 MaxoCore Pharmaceuticals
10.92 Medisyn Technologies
10.93 Merck & Co
10.94 MethylGene
10.95 Mitsubishi Tanabe Pharma
10.96 Molecular LogiX
10.97 NeoPharm
10.98 Nerviano Medical Sciences
10.99 NicOx
10.100 Nidus Laboratories
10.101 NIH - The US National Institute of Health
10.102 Nippon Shinyaku
10.103 Non-industrial Source
10.104 Novartis
10.105 Novogen
10.106 Oncalis
10.107 Onconova
10.108 OncoTherapy Science
10.109 Oncothyreon
10.110 OSI Pharmaceuticals
10.111 Pathway Therapeutics
10.112 Peregrine Pharmaceuticals
10.113 Pfizer
10.114 Pharmacyclics
10.115 PharmaGap
10.116 PharmaMar
10.117 Pharmexa
10.118 Phytomedics
10.119 Piramal
10.120 PIramed
10.121 Plexxikon
10.122 Provid
10.123 QLT
10.124 Quantum Pharmaceuticals
10.125 Ras Therapeutics
10.126 Reata Pharmaceuticals
10.127 Receptor BioLogix
10.128 Rexahn
10.129 Rigel
10.130 Sanofi-Aventis
10.131 Sareum
10.132 SBIO
10.133 Scancell
10.134 Schering-Plough
10.135 Semafore Pharmaceuticals
10.136 Sentinel Oncology
10.137 SGX Pharmaceuticals
10.138 Silence Therapeutics
10.139 Sirna Therapeutics
10.140 Sunesis
10.141 SuperGen
10.142 Supratek Pharma
10.143 Switch Pharma
10.144 Takeda
10.145 Targa Therapeutics
10.146 TargeGen
10.147 Tekmira Pharmaceuticals
10.148 Telik
10.149 Thallion Pharmaceuticals
10.150 Theryte
10.151 ToolGen
10.152 TopoTarget
10.153 UCB
10.154 VasGene Therapeutics
10.155 Velacor Therapeutics
10.156 Vertex Pharmaceuticals
10.157 ViroMed
10.158 Wyeth
10.159 Xcovery
10.160 Xencor

11 Disclaimer

12 Drug Index

13 Company Index

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Protein Kinase Drug Targets in Oncology
Figure 2: The Drug-Protein Interactome of Protein Kinase Drugs –Clusters I
Figure 3: The Drug-Protein Interactome of Protein Kinase Drugs – Clusters II
Figure 4: Head-to-Head Targeting Interactome of Protein Kinase Drugs
Figure 5: Distribution of Compound Types among Protein Kinase Drugs in Oncology
Figure 6: Primary Sub-cellular Localization of Drug Targets

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Protein Kinase Drug Targets in Oncology
Figure 2: The Drug-Protein Interactome of Protein Kinase Drugs –Clusters I
Figure 3: The Drug-Protein Interactome of Protein Kinase Drugs – Clusters II
Figure 4: Head-to-Head Targeting Interactome of Protein Kinase Drugs
Figure 5: Distribution of Compound Types among Protein Kinase Drugs in Oncology
Figure 6: Primary Sub-cellular Localization of Drug Targets
Table 4: Terminally Ceased Therapeutic Protein Kinase Targets in Oncology
Table 5: Drug Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 6: Identity of Protein Kinase Drug Targets with Available Biological Structures
Table 7: Number of Target-Target Interactions among Protein Kinase Drug Targets in Oncology
Table 8: Drug-Protein Interactome Clusters
Table 9: Protein Kinase Drug Targets with Available Protein Expression Profiles
Table 10: Pathway Summary
Table 11: Drug Targets without any Identified Assigned Pathways
Table 12: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology
Table 13: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology
Table 14: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology
Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness
Table 16: Top Competitive Protein Kinase Target Profiles in Oncology
Table 17: Terminated Drug Target Strategies of Protein Kinase Drugs in Oncology
Table 18 New and Unique Protein Kinase Target Strategies in Cancer Currently in Pre-Registration to Marketed
Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Protein Kinase Drugs in Oncology
Table 20: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase III Clinical Development
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology
Table 22: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase II Clinical Development
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology
Table 24 New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase I Clinical Development
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology
Table 26: New and Unique Protein Kinase Target Strategies in Oncology Currently in Preclinical Development
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology
Table 28: The Progression, Maturity and Competitive Comparison of Protein Kinase Drug Target Profiles in Cancer Drug Development
Table 29: Overview of Compound Strategy Competition Among Protein Kinase Drugs in Oncology
Table 30: Overview of the Competitive Landscape of Small Molecular Protein Kinase Drugs in Oncology
Table 31: Head-to-Head Target Competition Between Small Molecule Protein Kinase Drugs for the Treatment of Cancer
Table 32: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs of Protein Kinase Therapeutics in Oncology
Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Protein Kinase Drugs in Development
Table 34: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology
Table 35: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Protein Kinase Drugs in Development
Table 36: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology
Table 37: The Competition Through Close Mechanistic Approximation Between Protein Based Protein Kinase Drugs in Oncology
Table 38: The Progression, Maturity and Competitive Comparison of Protein Based Protein Kinase Drugs in Development
Table 39: Overview of the Competitive Landscape of Antibody Protein Kinase Drugs in Oncology
Table 40: The Competition Through Close Mechanistic Approximation Between Antibody Protein Kinase Drugs in Oncology
Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Protein Kinase Drugs in Development
Table 42: Overview of the Competitive Landscape of Nucleic Acid Therapy Protein Kinase Drugs in Oncology
Table 43: The Competition Through Close Mechanistic Approximation Between Nucleic Acid Therapy Protein Kinase Drugs in Oncology
Table 44: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Protein Kinase Drugs in Development
Table 45: Potential Forms of Cell Therapy
Table 46: Vectors in Gene Therapy
Table 47: The Progression, Maturity and Competitive Comparison of Target Profiles of Cell Therapy Based Protein Kinase Drugs in Development
Table 48: Overview of the Competitive Landscape of Gene Therapy Protein Kinase Drugs in Oncology
Table 49: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Based Protein Kinase Drugs in Development
Table 50: The Competition Through Close Mechanistic Approximation Among All Protein Kinase Drugs in Oncology
Table 51: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology
Table 52: Competitive Summary of Protein Kinase Drugs by Cancer Indication
Table 53: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia
Table 54: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs
Table 55: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia
Table 56: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs
Table 57: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer
Table 58: Drug Target Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma
Table 59: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs
Table 60: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer
Table 61: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Benign Prostatic Hyperplasia
Table 62: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer
Table 63: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer
Table 64: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs
Table 65: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer
Table 66: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer
Table 67: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs
Table 68: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer
Table 69: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs
Table 70: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Carcinoid
Table 71: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer
Table 72: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs
Table 73: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia
Table 74: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs
Table 75: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia
Table 76: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs
Table 77: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer
Table 78: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs
Table 79: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer
Table 80: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer
Table 81: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs
Table 82: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general)
Table 83: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs
Table 84: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer
Table 85: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs
Table 86: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer
Table 87: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs
Table 88: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer
Table 89: The Competition through Close Mechanistic Approximation between Head and Neck and Cancer Drugs
Table 90: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Hodgkin's Lymphoma
Table 91: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma
Table 92: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general)
Table 93: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma
Table 94: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer
Table 95: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs
Table 96: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general)
Table 97: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs
Table 98: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general)
Table 99: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs
Table 100: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia
Table 101: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Melanoma
Table 102: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs
Table 103: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma
Table 104: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs
Table 105: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome
Table 106: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs
Table 107: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myeloma
Table 108: The Competition through Close Mechanistic Approximation between Myeloma Drugs
Table 109: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer
Table 110: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma Cancer
Table 111: Drug Target Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin's Lymphoma
Table 112: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs
Table 113: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer
Table 114: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drug
Table 115: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer
Table 116: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs
Table 117: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer
Table 118: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma
Table 119: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer
Table 120: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs
Table 121: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer
Table 122: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs
Table 123: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer
Table 124: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs
Table 125: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer
Table 126: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs
Table 127: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer
Table 128: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs
Table 129: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma
Table 130: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general)
Table 131: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs
Table 132: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer
Table 133: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs
Table 134: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma
Table 135: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer
Table 136: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma
Table 137: Drug Target Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma
Table 138: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer
Table 139: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer
Table 140: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer
Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs
Table 142: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication
Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs
Table 144: 4SC's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 145: AB Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 146: Abbott's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 147: Abiogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 148: Abraxis BioScience's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 149: Advenchen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 150: AEgera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 151: Aeterna Zentaris’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 152: Aida Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 153: Alethia Biotherapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 154: Alfacell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 155: AlphaVax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 156: Ambit Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 157: Amgen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 158: Amphora's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 159: Apthera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 160: Ariad's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 161: Arno Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 162: ArQule's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 163: Array BioPharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 164: Astellas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 165: Astex Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 166: AstraZeneca's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 167: Avalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 168: Bayer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 169: Benitec's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 170: Berkeley Lab's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 171: BioAxone's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 172: Biotecnol's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 173: Biotica Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 174: Boehringer Ingelheim's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 175: Bristol-Myers Squibb's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 176: BTG's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 177: Calistoga Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 178: Callisto Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 179: Cambrex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 180: CanBas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 181: Cancer Research Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 182: Catalyst Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 183: Celgene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 184: Cell Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 185: Cephalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 186: Chroma Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 187: CompleGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 188: Compugen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 189: CoNCERT Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 190: Curis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 191: Cyclacel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 192: Cylene Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 193: Cytokine PharmaSciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 194: Cytopia's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 195: Dainippon Sumitomo Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 196: Deciphera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 197: DeveloGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 198: Dyax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 199: Eisai's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 200: Elara Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 201: Eli Lilly's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 202: Enkam Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 203: EntreMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 204: Exelixis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 205: Galapagos’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 206: Genentech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 207: Generex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 208: GlaxoSmithKline's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 209: GlycoGenesys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 210: GPC Biotech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 211: Hanmi's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 212: Hoffmann-La Roche's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 213: Hutchison China MediTech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 214: Idera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 215: ImClone Systems’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 216: ImmunoFrontier's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 217: Incyte Corporation's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 218: Inhibiton Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 219: Inovio's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 220: Insmed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 221: InterMune's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 222: ISU ABXIS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 223: Johnson & Johnson's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 224: KAI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 225: Kalypsys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 226: Keryx Biopharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 227: Kiadis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 228: Kirin Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 229: KuDOS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 230: Lexicon Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 231: Locus Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 232: Lorus Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 233: MaxoCore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 234: Medisyn Technologies’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 235: Merck & Co's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 236: MethylGene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 237: Mitsubishi Tanabe Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 238: Molecular LogiX's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 239: NeoPharm's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 240: Nerviano Medical Sciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out1116
Table 241: NicOx's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 242: Nidus Laboratories’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 243: NIH's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 244: Nippon Shinyaku's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 245: Non-industrial Source's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 246: Novartis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 247: Novogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 248: Oncalis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 249: Onconova's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 250: OncoTherapy Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 251: Oncothyreon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 252: OSI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 253: Pathway Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 254: Peregrine Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 255: Pfizer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 256: Pharmacyclics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 257: PharmaGap's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 258: PharmaMar's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 259: Pharmexa's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 260: Phytomedics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 261: Piramal's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 262: PIramed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 263: Plexxikon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 264: Provid's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 265: QLT's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 266: Quantum Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 267: Ras Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 268: Reata Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 269: Receptor BioLogix's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 270: Rexahn's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 271: Rigel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 272: Sanofi-Aventis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 273: Sareum's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 274: SBIO's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 275: Scancell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 276: Schering-Plough's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 277: Semafore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 278: Sentinel Oncology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 279: SGX Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 280: Silence Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 281: Sirna Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 282: Sunesis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 283: SuperGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 284: Supratek Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 285: Switch Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 286: Takeda's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 287: Targa Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 288: TargeGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 289: Tekmira Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 290: Telik's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 291: Thallion Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 292: Theryte's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 293: ToolGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 294: TopoTarget's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 295: UCB's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 296: VasGene Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 297: Velacor Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 298: Vertex Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 299: ViroMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 300: Wyeth's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 301: Xcovery's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Table 302: Xencor's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out

- SC
- AB Science
- Abbott
- Abiogen
- Abraxis BioScience
- Advenchen
- AEgera
- Aeterna Zentaris
- Aida Pharmaceuticals
- Alethia Biotherapeutics
- Alfacell
- AlphaVax
- Ambit Biosciences
- Amgen
- Amphora
- Apthera
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Astellas
- Astex Therapeutics
- AstraZeneca
- Avalon
- Bayer
- Benitec
- Berkeley Lab
- BioAxone
- Biotecnol
- Biotica Technology
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Calistoga Pharmaceuticals
- Callisto Pharmaceuticals
- Cambrex
- CanBas
- Cancer Research Technology
- Catalyst Biosciences
- Celgene
- Cell Therapeutics
- Cephalon
- Chroma Therapeutics
- CompleGen
- Compugen
- CoNCERT Pharmaceuticals
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- Cytokine PharmaSciences
- Cytopia
- Dainippon Sumitomo Pharma
- Deciphera Pharmaceuticals
- DeveloGen
- Dyax
- Eisai
- Elara Pharmaceuticals
- Eli Lilly
- Enkam Pharmaceuticals
- EntreMed
- Exelixis
- Galapagos
- Genentech
- Generex
- GlaxoSmithKline
- GlycoGenesys
- GPC Biotech
- Hanmi
- Hoffmann-La Roche
- Hutchison China MediTech
- Idera Pharmaceuticals
- ImClone Systems
- ImmunoFrontier
- Incyte Corporation
- Inhibiton Therapeutics
- Inovio
- Insmed
- InterMune
- ISU ABXIS
- Johnson & Johnson
- KAI Pharmaceuticals
- Kalypsys
- Keryx Biopharmaceuticals
- Kiadis
- Kirin Pharma
- KuDOS
- Kyowa Hakko Kirin
- Lexicon Pharmaceuticals
- Locus Pharmaceuticals
- Lorus Therapeutics
- MaxoCore Pharmaceuticals
- Medisyn Technologies
- Merck & Co
- MethylGene
- Mitsubishi Tanabe Pharma
- Molecular LogiX
- NeoPharm
- Nerviano Medical Sciences
- NicOx
- Nidus Laboratories
- NIH - The US National Institute of Health
- Nippon Shinyaku
- Non-industrial Source
- Novartis
- Novogen
- Oncalis
- Onconova
- OncoTherapy Science
- Oncothyreon
- OSI Pharmaceuticals
- Pathway Therapeutics
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Phytomedics
- Piramal
- PIramed
- Plexxikon
- Provid
- QLT
- Quantum Pharmaceuticals
- Ras Therapeutics
- Reata Pharmaceuticals
- Receptor BioLogix
- Rexahn
- Rigel
- Sanofi-Aventis
- Sareum
- SBIO
- Scancell
- Schering-Plough
- Semafore Pharmaceuticals
- Sentinel Oncology
- SGX Pharmaceuticals
- Silence Therapeutics
- Sirna Therapeutics
- Sunesis
- SuperGen
- Supratek Pharma
- Switch Pharma
- Takeda
- Targa Therapeutics
- TargeGen
- Tekmira Pharmaceuticals
- Telik
- Thallion Pharmaceuticals
- Theryte
- ToolGen
- TopoTarget
- UCB
- VasGene Therapeutics
- Velacor Therapeutics
- Vertex Pharmaceuticals
- ViroMed
- Wyeth
- Xcovery
- Xencor

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos